血浆KIM-1与CKD肾脏病理及肾功能衰竭风险的关系
基于波士顿肾脏活检队列(BKBC,524例)和CRIC研究(3,800例CKD患者)的前瞻性观察性研究,评估血浆KIM-1与肾脏病理病变及临床结局的关联。结果显示血浆KIM-1水平与急性肾小管损伤、肾小管间质炎症及系膜增生相关,且KIM-1每翻倍与肾衰竭风险升高独立相关(BKBC HR 1.19,CRIC HR 1.10),但与死亡无显著关联。
要点
- 血浆KIM-1升高与急性肾小管损伤、肾小管间质炎症及系膜增生等病理病变相关
- 在BKBC和CRIC两个队列中,血浆KIM-1每翻倍与肾衰竭风险增加独立相关
- 血浆KIM-1与死亡风险无统计学显著关联
核心结论
- 血浆KIM-1与潜在肾小管间质和系膜病变相关,并在两个肾脏疾病队列中与进展至肾衰竭相关。
研究设计与样本
- 前瞻性观察性队列研究,纳入BKBC研究524例接受临床指征原生肾活检的个体,以及CRIC研究3,800例常见形式CKD患者。
主要发现
- BKBC中,多变量调整后较高的血浆KIM-1与更严重的急性肾小管损伤、肾小管间质炎症及更严重的系膜扩张相关。
- BKBC中糖尿病肾病、肾小球疾病和肾小管间质疾病患者在多变量调整后血浆KIM-1水平显著更高。
- BKBC中124例进展至肾衰竭、85例死亡,中位随访5年;CRIC中1,153例进展至肾衰竭、1,356例死亡,中位随访11.5年。
- 两个队列中血浆KIM-1每翻倍与肾衰竭风险增加相关,BKBC的HR为1.19(95%CI,1.03-1.38),CRIC的HR为1.10(95%CI,1.06-1.15)。
- 两个队列中血浆KIM-1水平与死亡均无统计学显著关联。
关键数值与推荐
- 肾衰竭定义为启动肾脏替代治疗。
- BKBC中位随访5年,CRIC中位随访11.5年。
- BKBC肾衰竭HR 1.19(95%CI,1.03-1.38),CRIC肾衰竭HR 1.10(95%CI,1.06-1.15),均为血浆KIM-1每翻倍的多变量调整结果。
临床怎么用
- 血浆KIM-1可作为反映肾小管间质及系膜病变的无创生物标志物,辅助评估CKD患者进展至肾衰竭的风险。
局限性
- 研究结果的外推性受限,且存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Plasma kidney injury molecule 1 (KIM-1) is a sensitive marker of proximal tubule injury, but its association with risks of adverse clinical outcomes across a spectrum of kidney diseases is unknown. STUDY DESIGN: Prospective, observational cohort study. SETTING & PARTICIPANTS: 524 individuals enrolled into the Boston Kidney Biopsy Cohort (BKBC) Study undergoing clinically indicated native kidney biopsy with biopsy specimens adjudicated for semiquantitative scores of histopathology by 2 kidney pathologists and 3,800 individuals with common forms of chronic kidney disease (CKD) enrolled into the Chronic Renal Insufficiency Cohort (CRIC) Study. EXPOSURE: Histopathologic lesions and clinicopathologic diagnosis in cross-sectional analyses, baseline plasma KIM-1 levels in prospective analyses. OUTCOMES: Baseline plasma KIM-1 levels in cross-sectional analyses, kidney failure (defined as initiation of kidney replacement therapy) and death in prospective analyses. ANALYTICAL APPROACH: Multivariable-adjusted linear regression models tested associations of plasma KIM-1 levels with histopathologic lesions and clinicopathologic diagnoses. Cox proportional hazards models tested associations of plasma KIM-1 levels with future kidney failure and death. RESULTS: In the BKBC Study, higher plasma KIM-1 levels were associated with more severe acute tubular injury, tubulointerstitial inflammation, and more severe mesangial expansion after multivariable adjustment. Participants with diabetic nephropathy, glomerulopathies, and tubulointerstitial disease had significantly higher plasma KIM-1 levels after multivariable adjustment. In the BKBC Study, CKD in 124 participants progressed to kidney failure and 85 participants died during a median follow-up time of 5 years. In the CRIC Study, CKD in 1,153 participants progressed to kidney failure and 1,356 participants died during a median follow-up time of 11.5 years. In both cohorts, each doubling of plasma KIM-1 level was associated with an increased risk of kidney failure after multivariable adjustment (hazard ratios of 1.19 [95% CI, 1.03-1.38] and 1.10 [95% CI, 1.06-1.15] for BKBC and CRIC, respectively). There was no statistically significant association of plasma KIM-1 levels with death in either cohort. LIMITATIONS: Generalizability and unmeasured confounding. CONCLUSIONS: Plasma KIM-1 is associated with underlying tubulointerstitial and mesangial lesions and progression to kidney failure in 2 cohort studies of individuals with kidney diseases.
引用
- Schmidt IM, Srivastava A, Sabbisetti V, et al. Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies. Am J Kidney Dis. 2021. PMID: 34175376. doi:10.1053/j.ajkd.2021.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。